The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Research Funding - Moderna Therapeutics (Inst)
A phase I study of mRNA-2752, a lipid nanoparticle encapsulating mRNAs encoding human OX40L, IL-23, and IL-36γ, for intratumoral (iTu) injection alone and in combination with durvalumab.
 
Manish R. Patel
Honoraria - Bayer; Genentech; Janssen Oncology; Pfizer; Pharmacyclics
Consulting or Advisory Role - Pfizer/EMD Serono; Pharmacyclics/Janssen
Speakers' Bureau - Celgene; Exelixis; Genentech/Roche; Taiho Pharmaceutical
Research Funding - Acerta Pharma (Inst); ADC Therapeutics (Inst); Agenus (Inst); Aileron Therapeutics (Inst); AstraZeneca (Inst); Bicycle Therapeutics (Inst); BioNTech (Inst); Boehringer Ingelheim (Inst); Calithera Biosciences (Inst); Celgene (Inst); Checkpoint Therapeutics (Inst); CicloMed (Inst); Clovis Oncology (Inst); Curis (Inst); cyteir (Inst); Daiichi Sankyo (Inst); eFFECTOR Therapeutics (Inst); EMD Serono (Inst); Evelo Therapeutics (Inst); FORMA Therapeutics (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); H3 Biomedicine (Inst); Hengrui Therapeutics (Inst); Hutchison MediPharma (Inst); Ignyta (Inst); Incyte (Inst); Jacobio (Inst); Janssen (Inst); Jounce Therapeutics (Inst); Klus Pharma (Inst); Kyocera (Inst); Lilly (Inst); Loxo (Inst); LSK BioPharma (Inst); Lycera (Inst); Macrogenics (Inst); Merck (Inst); Millennium (Inst); Mirati Therapeutics (Inst); Moderna Therapeutics (Inst); Pfizer (Inst); Phoenix Molecular Designs (Inst); Placon (Inst); Portola Pharmaceuticals (Inst); Prelude Therapeutics (Inst); PubGene (Inst); QiLu Pharmaceutical (Inst); Revolution Medicines (Inst); Ribon Therapeutics (Inst); Seven and Eight Biopharmaceuticals (Inst); Stemline Therapeutics (Inst); Syndax (Inst); Synthorx (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Tesaro (Inst); TopAlliance BioSciences Inc (Inst); Vedanta Biosciences (Inst); Verastem (Inst); Vigeo Therapeutics (Inst); Xencor (Inst)
 
Todd Michael Bauer
Employment - Tennessee Oncology
Consulting or Advisory Role - Bayer; Blueprint Medicines; Exelixis; Foundation Medicine; Guardant Health; Ignyta (Inst); Loxo; Moderna Therapeutics (Inst); Pfizer; Pfizer (Inst)
Speakers' Bureau - Bayer
Research Funding - Abbvie (Inst); Aileron Therapeutics (Inst); Amgen (Inst); ARMO BioSciences (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Clovis Oncology (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Five Prime Therapeutics (Inst); Foundation Medicine (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Ignyta (Inst); Immunocore (Inst); Immunogen (Inst); Incyte (Inst); Jacobio (Inst); Janssen (Inst); Karyopharm Therapeutics (Inst); Kolltan Pharmaceuticals (Inst); Leap Therapeutics (Inst); Lilly (Inst); Loxo (Inst); MabVax (Inst); MedImmune (Inst); medpacto (Inst); Merck (Inst); Merrimack (Inst); Millennium (Inst); Mirati Therapeutics (Inst); Moderna Therapeutics (Inst); Novartis (Inst); Onyx (Inst); Peleton (Inst); Pfizer (Inst); Phosplatin Therapeutics (Inst); Principa Biopharma (Inst); Roche (Inst); Sanofi (Inst); Stemline Therapeutics (Inst); Takeda (Inst); Top Alliance BioScience (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Celgene; Clovis Oncology; EMD Serono; Genentech; Lilly; Merck; Novartis; Pfizer; Pharmacyclics; Sysmex
 
Antonio Jimeno
Stock and Other Ownership Interests - Champions Oncology; Suvica
Research Funding - Acerta Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Celldex (Inst); Genocea Biosciences (Inst); HolyStone Therapeutics (Inst); Iovance Biotherapeutics (Inst); Karyopharm Therapeutics (Inst); Kinex (Inst); MedImmune (Inst); Merck (Inst); Moderna Therapeutics (Inst); OncoMed (Inst); Pfizer (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - Suvica
 
Ding Wang
Consulting or Advisory Role - Qurgen; Qurgen
Travel, Accommodations, Expenses - Qurgen
 
Patricia LoRusso
Honoraria - Five Prime Therapeutics
Consulting or Advisory Role - Abbvie; Agenus; Agios; Astellas Pharma; AstraZeneca; Black Diamond Therapeutics; Cybrexa Therapeutics; CytomX Therapeutics; EMD Serono; Five Prime Therapeutics; Genentech; Genmab; GlaxoSmithKline; Halozyme; I-MAB; Immunome; IQvia; Macrogenics; Pfizer; QED Therapeutics; Roche/Genentech; Salarius Pharmaceuticals; Shattuck Labs; Silverback Therapeutics; Sotio; Takeda; Trial to Reduce IDDM in the Genetically at Risk (TRIGR); TYME
Research Funding - Genentech (Inst)
Travel, Accommodations, Expenses - Genentech
 
Khanh Tu Do
Consulting or Advisory Role - Jackson Laboratory for Genomic Medicine; QED Therapeutics; Seagen
Research Funding - Lilly (Inst)
 
Salomon M. Stemmer
Stock and Other Ownership Interests - canfite; CTG Pharma; DocBoxMD; tyrnovo; VYPE
Consulting or Advisory Role - Novartis
Research Funding - AstraZeneca (Inst); BiolineRx (Inst); Bristol-Myers Squibb (Inst); Can-Fite BioPharma (Inst); Clovis Oncology (Inst); CTG Pharma (Inst); Exelixis (Inst); Geicam (Inst); Halozyme (Inst); Incyte (Inst); Lilly (Inst); Moderna Therapeutics (Inst); MSD (Inst); Puma Biotechnology (Inst); Rafael Pharmaceuticals (Inst); Roche (Inst); Silenseed (Inst); SynCoreBio (Inst); Teva (Inst); Tiziana Life Sciences (Inst)
Travel, Accommodations, Expenses - Genomic Health
 
Corinne Maurice-Dror
No Relationships to Disclose
 
Ravit Geva
Leadership - Pyxis
Honoraria - Bristol-Myers Squibb; Janssen; Medison; MSD; Novartis; Pfizer; Roche; Takeda
Consulting or Advisory Role - Bayer; BOL Pharma; MSD; Novartis
Patents, Royalties, Other Intellectual Property - Options, BOL Pharma
Travel, Accommodations, Expenses - Bayer; Bristol-Myers Squibb; Medison; Merck Serono
 
Sima Zacharek
Employment - Moderna Therapeutics
Stock and Other Ownership Interests - Moderna Therapeutics
 
Andressa S Laino
Employment - Moderna Therapeutics
Stock and Other Ownership Interests - Moderna Therapeutics
 
Jing Sun
Employment - Moderna Therapeutics
Stock and Other Ownership Interests - Moderna Therapeutics
 
Joshua Frederick
Employment - Moderna Therapeutics
Stock and Other Ownership Interests - Moderna Therapeutics
Patents, Royalties, Other Intellectual Property - Moderna Therapeutics
 
Honghong Zhou
Employment - Moderna Therapeutics
Stock and Other Ownership Interests - Merck; Moderna Therapeutics
 
William Randolph
Employment - Moderna Therapeutics
Stock and Other Ownership Interests - Moderna Therapeutics; Novartis
 
Pamela Sarah Cohen
Employment - Moderna Therapeutics
Stock and Other Ownership Interests - Moderna Therapeutics
 
Robert S. Meehan
Employment - Moderna Therapeutics
Stock and Other Ownership Interests - Moderna Therapeutics
 
Ryan J. Sullivan
Consulting or Advisory Role - ACI Clinical; Array BioPharma; Asana Biosciences; Merck; Novartis; Replimune; Syndax; WorldCare Clinical, LLC
Research Funding - Aeglea Biotherapeutics (Inst); Amgen (Inst); Asana Biosciences (Inst); BioMed Valley Discoveries (Inst); Compugen (Inst); Deciphera (Inst); Lilly (Inst); Merck (Inst); Moderna Therapeutics (Inst); Neon Therapeutics (Inst); Pfizer (Inst); Roche/Genentech (Inst); Sanofi (Inst); Viralytics (Inst)
Other Relationship - Boehringer Ingelheim